Core Viewpoint - InspireMD, Inc. has officially launched the CGuard Prime carotid stent system in the U.S. after receiving FDA approval, marking a significant milestone in the company's expansion efforts [1][3]. Product Overview - The CGuard Prime is designed to minimize embolism risk by trapping potential emboli against the arterial wall while maintaining external carotid artery perfusion [2]. - Key features include a dual layer design with the largest open-cell frame and the smallest mesh pore size, a MicroNet™ bio-stable mesh made from a single 20 μm Polyethylene Terephthalate (PET) strand, and SmartFit™ technology for precise vessel wall apposition [2][4]. Market Position and Strategy - InspireMD has secured double-digit market share in over 30 countries and is prepared for a robust U.S. launch backed by a skilled commercial team [3]. - The company aims to establish its MicroNet mesh technology as the industry standard for carotid stenting, focusing on acute results and long-term stroke-free outcomes [5].